Moderna Q3 net income $1.0B, EPS $2.53; lowers 2022 sales view to $18-19B

Moderna, Inc.

2022-Q3 EPS reported $16.46 revenue$14,179,000,000

Q3 revenue $3.4B (down 32% YoY), GAAP net income $1.0B, diluted EPS $2.53 (down 67%).
Product sales $3.1B, down 35%; cost of sales 35% including $333M write-downs and $209M unutilized capacity.
2022 sales guidance lowered to $18-19B ($2-3B deferred to 2023); 2023 preliminary APAs $4.5-5.5B.
Completed $3B buyback; new $3B program underway; cash $17.0B.
Pipeline: PCV Phase 2 data Q4 2022; RSV Phase 3 data this winter; flu Phase 3 data Q1 2023; $250M from Merck.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moderna, Inc. reported third quarter ended September 30, 2022 results: revenue $3.4 billion, net income $1.0 billion, EPS $2.53. Guidance reaffirmed.

Period: third quarter ended September 30, 2022
Revenue: $3.4 billion
Net income: $1.0 billion
EPS: $2.53
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates Third quarter 2022 revenues of $3.4 billion ; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53

View on SEC.gov

Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-22-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.